Impact of a synchronous prophylactic treatment of the anterior accessory saphenous vein on the recurrent varicose vein rate in patients undergoing thermal ablation of an insufficient great saphenous vein (SYNCHRONOUS-Study): study protocol for a prospective, multicentre, controlled observational study.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
22 06 2022
Historique:
entrez: 22 6 2022
pubmed: 23 6 2022
medline: 25 6 2022
Statut: epublish

Résumé

To date, there are no prospective studies evaluating the prevention of recurrent veins by the simultaneous treatment of a sufficient anterior accessory saphenous vein (AASV) in patients undergoing endovenous laser ablation (EVLA) of an insufficient great saphenous vein (GSV). This study will provide important information about the impact of the AASV on the development of recurrent veins after EVLA of the GSV. Additionally, it will be clarified whether patients benefit from a preventive ablation of a sufficient AASV. This is a multicentre, prospective, controlled, exploratory clinical study in 1150 patients with a medical indication for EVLA of a refluxing great saphenous vein. Patients will be enrolled into two study groups: in half of the patients EVLA will be performed on the insufficient GSV only. In the other half of the patients EVLA will be performed on the insufficient GSV and additionally on the sufficient AASV. Within seven study visits, patients will be followed-up over a time period of 5 years. Primary study endpoint is the recurrence rate; secondary endpoints include inter alia, complication rate, postoperative pain intensity, quality of life and patient satisfaction. Before initiation of the study, the protocol was presented and approved by the independent ethics committee of the medical faculty of the University of Heidelberg (Ethics approval number S-596/2018). This study was prospectively registered at the German Clinical Trial Register (https://www.germanctr.de/). Research findings will be disseminated in a peer-reviewed journal and at relevant conferences. German Clinical Trial Registry (DRKS00015486).

Identifiants

pubmed: 35732403
pii: bmjopen-2022-061530
doi: 10.1136/bmjopen-2022-061530
pmc: PMC9226876
doi:

Types de publication

Clinical Trial Protocol Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e061530

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

J Vasc Surg. 2000 Jun;31(6):1307-12
pubmed: 10842165
Ann R Coll Surg Engl. 2003 Nov;85(6):389-92
pubmed: 14629879
J Vasc Surg Venous Lymphat Disord. 2020 Jul;8(4):505-525.e4
pubmed: 32139328
Angiology. 2019 May;70(5):388-396
pubmed: 29874921
J Dtsch Dermatol Ges. 2017 May;15(5):538-556
pubmed: 28485865
J Vasc Surg. 2013 Mar;57(3):860-8
pubmed: 23343668
Arch Dermatol. 2012 Jan;148(1):49-58
pubmed: 21931012
Br J Surg. 2008 Mar;95(3):294-301
pubmed: 18278775
Eur J Vasc Endovasc Surg. 2010 Nov;40(5):649-56
pubmed: 20888274
J Vasc Surg. 1999 Oct;30(4):710-9
pubmed: 10514210
Br J Surg. 2008 Oct;95(10):1232-8
pubmed: 18763255
Br J Surg. 2011 Aug;98(8):1079-87
pubmed: 21725957
Eur J Vasc Endovasc Surg. 2008 Aug;36(2):207-210
pubmed: 18524645
ScientificWorldJournal. 2014 Jan 27;2014:505843
pubmed: 24592172
Dermatol Surg. 2005 Dec;31(12):1685-94; discussion 1694
pubmed: 16336888
Br J Surg. 1994 Feb;81(2):167-73
pubmed: 8156326
J Vasc Surg. 2010 Nov;52(5):1234-41
pubmed: 20801608
Cardiovasc Surg. 2000 Jun;8(4):233-45
pubmed: 10950599

Auteurs

Christine Fink (C)

Department of Dermatology, University Hospital Heidelberg, Heidelberg, Germany christine.fink@med.uni-heidelberg.de.

Karsten Hartmann (K)

Venenzentrum Freiburg, Freiburg, Germany.

Thomas Mattausch (T)

Venenzentrum am Brühl, Leipzig, Germany.

Hans-Christian Wenzel (HC)

Venenzentrum am Brühl, Leipzig, Germany.

Phillip Zollmann (P)

MVZ Dr. Zollmann und Kollegen, Jena, Germany.

Jürgen Veltman (J)

MVZ Dr. Zollmann und Kollegen, Jena, Germany.

Thomas Weiler (T)

Venenzentrum Pforzheim, Pforzheim, Germany.

Guido Lengfellner (G)

Venen-Fachpraxis Regensburg, Regensburg, Germany.

Lars Müller (L)

Department of Vascular Surgery, Dermatologikum Hamburg, Hamburg, Germany.

Markus Stücker (M)

Department of Dermatology, Ruhr-Universität Bochum, Bochum, Germany.

Felizitas Pannier (F)

Praxis Dr. Pannier, Bonn, Germany.

Carmen Dietrich (C)

Department of Dermatology, University of Heidelberg, Heidelberg, Germany.

Lorenz Uhlmann (L)

Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany.

Tobias Hirsch (T)

Praxis für Innere Medizin und Gefäßkrankheiten, Venen Kompetenz-Zentrum, Halle (Saale), Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH